Human Epidermal Growth Factor Receptor 2 (HER2) PET Imaging of HER2-Low Breast Cancer with [<sup>68</sup>Ga]Ga-ABY-025: Results from a Pilot Study-Reference-Cited by-同舟云学术

Human Epidermal Growth Factor Receptor 2 (HER2) PET Imaging of HER2-Low Breast Cancer with [⁶⁸Ga]Ga-ABY-025: Results from a Pilot Study

Published:2024-03-28 Issue:5 Volume:65 Page:700-707
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Altena Renske,Burén Siri af,Blomgren August,Karlsson Emelie,Tzortzakakis Antonios,Brun Nikolai,Moein Mohammad M.,Jussing Emma,Frejd Fredrik Y.,Bergh Jonas,Tran Thuy A.,Hartman Johan,Axelsson Rimma

Publisher

Society of Nuclear Medicine

Reference23 articles.

1. HER2-Low Breast Cancer: Pathological and Clinical Landscape

2. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer;Schettini;npj Breast Cancer.,2021

3. Evolution of low HER2 expression between early and advanced-stage breast cancer;Tarantino;Eur J Cancer.,2022

4. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study

5. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Whole-Body HER2 Heterogeneity Identified on HER2 PET in HER2-Negative, -Low, and -Positive Metastatic Breast Cancer;Journal of Nuclear Medicine;2024-09-05

2. Trends in cancer imaging;Trends in Cancer;2024-09

3. Affibody PET Imaging of HER2-Expressing Cancers as a Key to Guide HER2-Targeted Therapy;Biomedicines;2024-05-14

4. The EANM-SNMMI guideline on the role of [18F]FDG-PET/CT in breast cancer: Important milestones and perspectives for the future;European Journal of Nuclear Medicine and Molecular Imaging;2024-05-13